A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injections(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optin Neuropathy (NAION)
1. To assess the safety and tolerability of QPI-1007 intravitreal (IVT) injections in subjects with recent-onset NAION 2. To determine the effect on visual function of QPI-1007 IVT injections in subjects with recent-onset NAION Location: University of Colorado Hospital |
A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran
To assess the safety and efficacy of long-term dosing with patisiran in transthyretin-mediated amyloidosis (ATTR) patients with familial amyloidotic polyneuropathy (FAP). Location: University of Colorado Hospital |
An Open-Label, Phase 3 Study Examining the Long-Term Safety Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
To evaluate the safety and tolerability of APL-130277 in patients with Parkinson's disease (PD) over a 24 week period Location: University of Colorado Hospital |
Collaborative International Research in Clinical and Longitudinal Experience for Neuromyelitis Optica (NMO) Studies
To create a longitudinal collections of samples and data from: 1. Subjects with clinically-defined or highly suspicious for NMO or NMOSD; 2. Affected or unaffected relatives of subjects with clinically defined NMO or NMOSD; 3. Subjects with autoimmune diseases other NMO or NMOSD, such as multiple sclerosis, myasthenia gravis, Graves' disease, lupus, etc. 4. Healthy subjects Location: University of Colorado Hospital |
A Double-Masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD. Location: University of Colorado Hospital |
NAtalizumab for Prevention of Post-partum Relapses in patients with Multiple Sclerosis 09May2016
To assess the efficacy of IV administered natalizumab, monthly for 1 year, in preventing relapses during the postpartum period. Location: University of Colorado Hospital |
Wireless electroencephalography for continuous monitoring in the EEG LTM unit 12Apr2018
1. To evaluate the device?s ability to record wireless EEG from patients in the long-term EEG monitoring unit 2. To compare wireless EEG in these recordings to standard-of-care wired EEG Location: University of Colorado Hospital |
A Phase IV Trial of Neuroprotection with ACTH in Acute Optic Neuritis |
Rocky Mountain Alzheimer's Disease Center at the University of Colorado School of Medicine (RMADC at UCSOM) Longitudinal Biomarker and Clinical Phenotyping Study
To create a repository of data and samples to be used to answer future research questions Location: University of Colorado Hospital |
A Phase 3, Open-Label Study of the Safety, Efficacy, and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients with Unsatisfactory Control on Available Therapy.
To assess the long-term safety of apomorphine continuous infusion in advanced Parkinson?s disease (PD) patients who are unable to achieve adequate motor control despite optimal treatment with noninvasive therapy. Location: University of Colorado Hospital |
A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312
To demonstrate the efficacy of BAF312 relative to placebo in delaying the time to 3-month confirmed disability progression in patients with SPMS as measured by EDSS. Location: University of Colorado Hospital |
Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological Disorders |
Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study
To demonstrate the superiority of MD1003, 300 mg/day, over placebo to clinically improve patients with progressive multiple sclerosis (MS). Location: University of Colorado Hospital |
Deep Brain Stimulation (DBS) of the Rostral Zona Incerta (rZI) for Parkinson's Disease (PD): Stereotactic Targeting and Clinical Efficacy |
Cognition and Neurodevelopmental Influence (CANDI) |
10-1311 DoneSave Functional connectivity of the motor network in two major subtypes of Parkinson Disease December 24,2015 |
Dystonia Coalition Project 1: Natural History and Biospecimen Repository for Dystonia |
MULTICENTER 1-YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM |
Diagnostic and Rating Tools for Blepharospasm |
Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE) Study |
Evaluating the Tolerability and Safety Profile of Switching from Rituximab to Ocrelizumab: A Real World Evaluation of Patients with Relapsing Forms of Multiple Sclerosis |
Using Next Generation Sequencing to Unravel the Pathogenesis of Sporadic Inclusion Body Myositis (IBM) - The International IBM Consortium Genetic Study |
A PHASE 1B/2, MULTI-CENTER, DOUBLE-BLIND (PRINCIPAL INVESTIGATORS AND STUDY SUBJECTS BLINDED, SPONSOR UNBLINDED), PLACEBO-CONTROLLED, RANDOMIZED, SINGLE-ASCENDING DOSE STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DS-1040B IN SUBJECTS WITH ACUTE ISCHEMIC STROKE |
Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY) |
BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services: The BEST-MSU Study |
The modified Atkins diet in patients with drug resistant epilepsy and the responsive neurostimulator 09Aug2017 |
Calibrating free-living physical activity characteristics across functionally-limited populations using machine-learned accelerometer approachesRegular physical activity is known to have positive effects on many health outcomes. In research, physical activity is often measured using activity monitors worn on the hip, wrist or ankle. These instruments determine how much physical activity a person does based on the amount of movement the person does. This is done with equations that use the data collected by the activity monitors. However, these equations are usually developed using measurements on healthy people. People who have movement disorders related to diseases such as Parkinson?s and Multiple Sclerosis, or conditions such as knee replacement, stroke, or arthritis have very different movement patterns than people without these diseases. Thus, the equations used to convert activity monitor data will not work well in people with these diseases or conditions. The purpose of this study is to develop equations to measure physical activity using activity monitors in people with movement limitations. Rather than creating specific equations for each individual disease and condition, we will perform simple tests to measure upper and lower body function, and then group people into different clusters based on these tests. Our preliminary studies show that these equations are more accurate than equations based on specific diseases or conditions.
Locations: CTRC-adult; University of Colorado Hospital |
Transcranial electrical stimulation for the treatment of cervical dystonia |
Topiramate as a disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN) |
Protocol I7S-MC-HBEH Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD) (The PRESENCE Study) |
Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM) |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson's Disease |
Management of Acute Stroke Patients on Treatment with New Oral Anticoagulants: Addressing Realworld Anticoagulant Management Issues in Stroke (ARAMIS) Registry
The ARAMIS registry is designed to provide important and timely insight into the management of acute stroke patients who are on novel oral anticoagulant in community practice Locations: Medical Center of the Rockies; Poudre Valley Hospital |
A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY OF CK-2127107 IN TWO ASCENDING DOSE COHORTS OF PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA) |
Phase 2 Study of Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke - CoBIS 2
The primary objective of the study is to determine, in a randomized, placebo controlled trial, the efficacy of a single intravenous (IV) infusion of unrelated donor UCB for improving functional outcomes in patients with ischemic stroke. The secondary objectives are as follows: 1.To describe the safety and tolerability of a single IV infusion of unrelated donor UCB in patients with ischemic stroke 2.To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement of neurological symptoms following ischemic stroke 3.To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement in quality of life and emotional and cognitive status in patients with ischemic stroke Location: University of Colorado Hospital |
American Registry for Migraine Research
Locations: Lone Tree Medical Center; UCHealth Internal Medical Clinic - Lowry; University of Colorado Hospital |
A randomized, double blind, placebo-controlled parallel study of tolerability and efficacy of Cannabidiol (CBD) on tremor in Parkinson's disease |
Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy |
Risk factors in Early Multiple Sclerosis (RisE-MS)
among asymptomatic first degree relatives (FDRs), aged 18-30, of multiple sclerosis (MS) patients: 1: Determine the prevalence of brain/spine MRI lesions disseminated in space (DIS), consistent with MS 2: Gather data on potential risk factors or early signs related to MS development, including markers for: genes, immunological function, environmental factors, neuroaxonal damage, Vitamin D levels, lipid metabolism, activity levels, mood abnormalities, and cognitive function. From this, develop a risk factor score, incorporating all relevant potential markers of increased risk of DIS. 3: To use this pilot, cross-sectional study as a base for development of a long-term, longitudinal, multi-center study to determine genetic and environmental risks for pre-symptomatic MS 4: To create and maintain a biobank of specimens for future analysis as other potential biomarkers become available. Location: University of Colorado Hospital |
Determining the Optimal Treatment Strategy for Patients who have Chronic Migraine with Medication Overuse |
Validation of a performance-based assessment of functional ability related to cognition in Parkinson's disease
Locations: Colorado Research Center; Department Specific Free Standing Clinic; University of Colorado Hospital |
A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients with Parkinson's Disease |
Clinical Trial Readiness for SCA1 and SCA3 |
Perceived palliative care needs of Huntington's disease patients |
Application of transcranial alternating current stimulation for modulation of sleep and cognitive performance
1).Optimize tACS parameters for duration, intensity and frequencies via utilization of EEG data recorded during tACS stimulation. 2)Determine whether recording artifacts introduced by tACS can confidently be removed from EEG signals. 3). Determine effects of tACS delivered with nested frequencies(multi-frequency signal) vs single frequency tACS, with regard to intrinsic EEG signal, for modulation of SWA coherence and power, as recorded in our overnight EEG sleep data. 4). Determine the cumulative effects of tACS delivered in multiple, consecutive nights on underlying EEG signals, sleep architecture, sleep quality and cognitive function among patients with MCI. 5). Determine if tACS is a viable treatment for disturbances of sleep and cognitive performance among patients with MCI. 6). Generate pilot data and manuscripts to support applications for larger randomized placebo-controlled clinical trials. Locations: Colorado Research Center; Department Specific Free Standing Clinic; University of Colorado Hospital |
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) |
Diet and Relapses in Pediatric Multiple Sclerosis |
AMPLATZERTM PFO Occluder Post Approval Study |
A 3-ARM, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies |
Automatic measurement of hand movements toward development of an objective assessment of primary motor symptoms in Parkinson?s disease |
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy |
A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease with Motor Fluctuations |
Multi-center, randomized, double-blinded assessment of Tecfidera? in extending the time to a first attack in radiologically isolated syndrome (RIS) (ARISE) |
Ruptured Aneurysms Treated with Hydrogel Coils
To determine occlusion rates and safety when hydrogel coils are used in the treatment of ruptured intracranial aneurysms. Location: Memorial Hospital Central |
COG ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) |
Neurologic Music Therapy for enhancing fine motor control in Parkinson's Disease 16Apr2018 |
Microburst VNS Therapy Feasibility Study in Patients with Refractory Epilepsy |
More than a Movement Disorder: Applying Palliative Care to Parkinson?s Disease v: 12/06/2017 |
Conversational Speech in the Diagnosis of Neurocognitive Disorders |
A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled Trial of VTS-270 (2-hydroxypropyl-a-cyclodextrin) in Subjects with Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease |
Peripheral Inflammatory Cytokine Levels in Parkinson Disease |
A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy STELLAR Study |
Clinical Outcome Measures in Friedreich's Ataxia |
Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis (DELIVERMS) |
A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects with Spinocerebellar Ataxia |
A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS |
Genomic Translation for ALS Care |
An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis |
Safety and Efficacy Study of Elezanumab (ABT-555) in Progressive Forms of Multiple Sclerosis |
Safety and Efficacy Study of Elezanumab (ABT-555) in Relapsing Forms of Multiple Sclerosis |
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults with Generalized Myasthenia Gravis |
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DNL201 IN SUBJECTS WITH PARKINSON'S DISEASE |
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) |
Association of depth recordings from the temporal cortex with sleep pattern detection and characterization of sleep dysfunction in patients with refractory epilepsy. |
Investigating the Contribution of Peripheral versus Central Nervous System Immune Dysfunction to Cognitive Aging |
Gene Expression of Cerebral AneurysmsIn this study, we will collect tissue and blood from participants during their epilepsy surgery.
Location: University of Colorado Hospital |
A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment
Locations: Brain Imaging Center (BIC); Colorado Research Center; University of Colorado Hospital |
Investigating cortical networks disruption and rehabilitation after traumatic brain injury |
Bedside Resources to Gauge Intravascular Volume Status in Hypovolemic Infants in the Operating Room |
A MULTICENTER, OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT |
A Natural History Study of CMT1B, CMT2A, CMT4A and CMT4C |
Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion |
AMPLATZERTM PFO Occluder Post Approval StudyThis is a single arm, multi-center study to confirm the safety and effectiveness of the AMPLATZERTM PFO Occluder in the post approval setting To demonstrate safety of the AMPLATZERTM PFO Occluder by assessing the 30-day rate of device- or procedure-related serious adverse events including those that led to death and the effective by assessing the rate of recurrent ischemic stroke through 5 years Location: Memorial Hospital Central |
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma |
A 14-Week, Double-Blind, Randomized, Three-Arm, Parallel Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease (gLIDe) |
A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebocontrolled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure |
Instrumentation of Huntington's Disease Motor Function Assessment |
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD˗9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure |
An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients with Generalized Myasthenia Gravis |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naive Adult Patients With Generalized Myasthenia Gravis |
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction |
A Two-year Prospective Natural History Study Examining the Use of Neuronal Injury Biomarkers in Autoimmune Encephalitis as a Potential Biomarker for Disease Activity and Severity
Locations: Brain Imaging Center (BIC); Childrens Hospital Colorado; Colorado Research Center; University of Colorado Hospital |
Gamma band neural stimulation and its effects on resting state networks |
Identifying relevant seizure biomarkers from RNS? System recorded electrocorticography for the development of optimized seizure detection algorithms |
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS |
Neurological Screening of Controls in an Age-Related Macular Degeneration Registry |
GORE? CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO): the REDUCE Post Approval StudyThis study will assess the safety and effectiveness of GORE? CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.
Locations: Harmony Campus; Medical Center of the Rockies |
A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects with Epilepsy with a Predictable Seizure Pattern |
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB) |
Comparative Effectiveness Research for Infantile Spasms V: 12Jan2017 |